Figures & data
Figure 1 Ten-point photonumeric masseter prominence rating scale for females.
Figure 2 The Merz five-point photonumeric facial shape categories for females.
Figure 3 Overview of the standardized masseter improvement measurements.
Figure 4 Patient at baseline (A), week 6 (B), week 16 (C), and week 20 (D) after the injection of incobotulinumtoxinA using MIT for the treatment of masseter hypertrophy.
Figure 5 Patient at baseline (A), week 6 (B), week 16 (C), and week 20 (D) after the injection of incobotulinumtoxinA using SIT for the treatment of masseter hypertrophy.
Figure 6 Patient at baseline (A), week 6 (B), week 16 (C), and week 20 (D) after an MIT of incobotulinumtoxinA in the masseters for the treatment of masseter hypertrophy.
Figure 7 Baseline and visit 3 (week 16) photos superimposed, for three patients treated with incobotulinumtoxinA for masseter hypertrophy.
Table 1 Mean and SD of the ICM angle and MM to midline distance for nonclenching and clenching data on the right and left sides of the face
Table 2 Results of paired samples’ t-tests for the ICM angle and MM to midline distance for nonclenching and clenching data on the right and left sides of the face
Table 3 Mean and SD of the ICM angle and MM to midline distance of the SIT and MIT groups at all visits for nonclenching data on both sides of the face
Table 4 Mean and SD of the ICM angle and MM to midline distance of the SIT and MIT groups at all visits for clenching data on both sides of the face
Table 5 Results of the Patient Satisfaction Questionnaire at visits 2–4
Table 6 Results of the physician-evaluated Global Aesthetic Improvement Scale at visits 2–4